Mao Li-Jun, Kan Yi, Li Bing-Heng, Ma Sai, Liu Yirui, Yang Dong-Liang, Yang Chunhua
Department of Urology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical University, Xuzhou, China.
Front Oncol. 2020 Apr 3;10:421. doi: 10.3389/fonc.2020.00421. eCollection 2020.
Prostate cancer is a common malignant tumor and the second leading cause of cancer-related death in men. Radiation therapy is a curative treatment for localized prostate cancer and has a limited effect for castration-resistant prostate cancer (CRPC). Interleukin 24 (IL-24) has a radiosensitizing effect in cancer cells. Our previous studies showed that ZD55-IL-24, an oncolytic adenovirus harboring IL-24, had better anti-tumor effect with no toxicity to normal cells. In this study, we evaluated the synergistic anti-tumor effect of oncolytic adenovirus ZD55-IL-24 combined with radiotherapy in prostate cancer. and experiments showed that the combined therapy significantly inhibited the growth of prostate cancer and provoked apoptosis of prostate cancer cells. In conclusion, the combination of ionizing radiation and oncolytic adenovirus expressing IL24 could achieve synergistic anti-tumor effect on prostate cancer, and is a promising strategy for prostate cancer therapy.
前列腺癌是一种常见的恶性肿瘤，是男性癌症相关死亡的第二大主要原因。放射治疗是局限性前列腺癌的一种根治性治疗方法，对去势抵抗性前列腺癌（CRPC）的效果有限。白细胞介素24（IL-24）在癌细胞中具有放射增敏作用。我们之前的研究表明，携带IL-24的溶瘤腺病毒ZD55-IL-24具有更好的抗肿瘤效果，且对正常细胞无毒性。在本研究中，我们评估了溶瘤腺病毒ZD55-IL-24联合放疗在前列腺癌中的协同抗肿瘤作用。实验表明，联合治疗显著抑制了前列腺癌的生长，并诱导了前列腺癌细胞的凋亡。总之，电离辐射与表达IL24的溶瘤腺病毒联合应用可对前列腺癌产生协同抗肿瘤作用，是一种有前景的前列腺癌治疗策略。
